Key points are not available for this paper at this time.
MS can be the first choice for EBD in patients undergoing NACRT for pancreatic head cancer. MS may be less costly overall.
Kobayashi et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: